Hui Sheng Chen

Dr. Hui Sheng Chen

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2022 in JAMA
Verified
Journal Article
Open access
PDF file
HCHui Sheng Chen
Hui Sheng Chen
YCYu Cui
Yu Cui
XLXiao-Qiu Li
Xiao-Qiu Li
XWXin-Hong Wang
Xin-Hong Wang
YMYu-Tong Ma
Yu-Tong Ma
JFJuan Feng
Juan Feng
Reperfusion therapies, including intravenous thrombolysis and endovascular thrombectomy, have been recommended as the most effective strategy for acute ischemic stroke (AIS) by current guidelines.1 In 2012, an estimated 37% of patients had a good prognosis through intravenous thrombolysis,2 and a 2016 meta-analysis estimated that about 46% of patients with large artery occlusion had a good outcome after endovascular therapy.3 Nevertheless, only a small proportion of the population can be treated with reperfusion therapies due to the limited therapeutic window and technical requirements. An active area of research has been to find new neuroprotective strategies to reduce the disability of AIS.4,5


28 February 2023 in JAMA
Verified
Journal Article
Open access
PDF file
HCHui Sheng Chen
Hui Sheng Chen
YCYu Cui
Yu Cui
ZZZhong-He Zhou
Zhong-He Zhou
GLGao-Hua Li
Gao-Hua Li
ZPZhao-Long Peng
Zhao-Long Peng
WYWen-Hai Yang
Wen-Hai Yang
Importance: Previous studies suggested a benefit of argatroban plus alteplase (recombinant tissue-type plasminogen activator) in patients with acute ischemic stroke (AIS). However, robust evidence in trials with large sample sizes is lacking.Objective: To assess the efficacy of argatroban plus alteplase for AIS.Design, Setting, and Participants: This multicenter, open-label, blinded end point randomized clinical trial including 808 patients with AIS was conducted at 50 hospitals in China with enrollment from January 18, 2019, through October 30, 2021, and final follow-up on January 24, 2022.Interventions: Eligible patients were randomly assigned within 4.5 hours of symptom onset to the argatroban plus alteplase group (n = 402), which received intravenous argatroban (100 μg/kg bolus over 3-5 minutes followed by an infusion of 1.0 μg/kg per minute for 48 hours) within 1 hour after alteplase (0.9 mg/kg; maximum dose, 90 mg; 10% administered as 1-minute bolus, remaining infused over 1 hour), or alteplase alone group (n = 415), which received intravenous alteplase alone. Both groups received guideline-based treatments.Main Outcomes and Measures: The primary end point was excellent functional outcome, defined as a modified Rankin Scale score (range, 0 [no symptoms] to 6 [death]) of 0 to 1 at 90 days. All end points had blinded assessment and were analyzed on a full analysis set.Results: Among 817 eligible patients with AIS who were randomized (median [IQR] age, 65 [57-71] years; 238 [29.1%] women; median [IQR] National Institutes of Health Stroke Scale score, 9 [7-12]), 760 (93.0%) completed the trial. At 90 days, 210 of 329 participants (63.8%) in the argatroban plus alteplase group vs 238 of 367 (64.9%) in the alteplase alone group had an excellent functional outcome (risk difference, −1.0% [95% CI, −8.1% to 6.1%]; risk ratio, 0.98 [95% CI, 0.88-1.10]; P = .78). The percentages of participants with symptomatic intracranial hemorrhage, parenchymal hematoma type 2, and major systemic bleeding were 2.1% (8/383), 2.3% (9/383), and 0.3% (1/383), respectively, in the argatroban plus alteplase group and 1.8% (7/397), 2.5% (10/397), and 0.5% (2/397), respectively, in the alteplase alone group.Conclusions and Relevance: Among patients with acute ischemic stroke, treatment with argatroban plus intravenous alteplase compared with alteplase alone did not result in a significantly greater likelihood of excellent functional outcome at 90 days.Trial Registration: ClinicalTrials.gov Identifier: NCT03740958

1 February 2021 in JACC
Verified
Journal Article
Closed access
LTLin Tao
Lin Tao
XLXiao-Qiu Li
Xiao-Qiu Li
XHXiao-Wen Hou
Xiao-Wen Hou
BYBen-Qiang Yang
Ben-Qiang Yang
CXCheng Xia
Cheng Xia
HCHui Sheng Chen
Hui Sheng Chen

1 October 2020 in Experimental Neurology
Verified
Journal Article
Closed access
DMDai-Chao Ma
Dai-Chao Ma
NZNan-Nan Zhang
Nan-Nan Zhang
YZYi-Na Zhang
Yi-Na Zhang
HCHui Sheng Chen
Hui Sheng Chen

1 March 2021 in Stroke
Verified
Journal Article
Closed access
PDF file
HSHongfei Sang
Hongfei Sang
FLFengli Li
Fengli Li
JYJunjie Yuan
Junjie Yuan
SLShuai Liu
Shuai Liu
WLWeidong Luo
Weidong Luo
FLFangfei Li
Fangfei Li
Background and Purpose: This study aimed to analyze the impact of baseline posterior circulation Acute Stroke Prognosis Early Computed Tomography Score (pc-ASPECTS) on the efficacy and safety of endovascular therapy (EVT) for patients with acute basilar artery occlusion. Methods: The BASILAR was a nationwide prospective registry of consecutive patients with a symptomatic and radiologically confirmed acute basilar artery occlusion within 24 hours of symptom onset. We estimated the effect of standard medical therapy alone (SMT group) versus SMT plus EVT (EVT group) for patients with documented pc-ASPECTS on noncontrast CT, both as a categorical (0–4 versus 5–7 versus 8–10) and as a continuous variable. The primary outcomes included favorable functional outcomes (modified Rankin Scale ≤3) at 90 days and mortality within 90 days. Results: In total, 823 cases were included: 468 with pc-ASPECTS 8 to 10 (SMT: 71; EVT: 397), 317 with pc-ASPECTS 5 to 7 (SMT: 85; EVT: 232), and 38 with pc-ASPECTS 0 to 4 (SMT: 13; EVT: 25). EVT was associated with higher rate of favorable outcomes (adjusted relative risk with 95% CI, 4.35 [1.30–14.48] and 3.20 [1.68–6.09]; respectively) and lower mortality (60.8% versus 77.6%, P =0.005 and 35.0% versus 66.2%, P< 0.001; respectively) than SMT in the pc-ASPECTS 5 to 7 and 8 to 10 subgroups. Continuous benefit curves also showed the superior efficacy and safety of EVT over SMT in patients with pc-ASPECTS ≥5. Furthermore, the prognostic effect of onset to puncture time on favorable outcome with EVT was not significant after adjustment for pc-ASPECTS (adjusted odds ratio, 0.98 [95% CI, 0.94–1.02]). Conclusions: Patients of basilar artery occlusion with pc-ASPECTS ≥5 could benefit from EVT. The baseline pc-ASPECTS appears more important for decision making and predicting prognosis than time to EVT. Registration: URL: http://www.chictr.org.cn . Unique identifier: ChiCTR1800014759.